Investment
Features
FeesSafety
Academy
More
Pluang+

Compare InMode Ltd (INMD) vs Mesoblast Limited (MESO) Price & Performance

InMode LtdTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

InMode Ltd vs Mesoblast Limited — how do they compare? InMode Ltd trades at $15.2 (market cap $872.08M), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 2.5× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

INMDMESO
Market Cap
$872.08M$2.21B
Sector
TechnologyTechnology
52-Week High
$16.62$20.96
52-Week Low
$12.76$12.88
Enterprise Value
$375.42M$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

InMode Ltd

InMode (INMD) trades at $15.17, down slightly by 0.13% today, with neutral technical signals and mixed earnings performance. The company maintains strong profitability with 76.52% gross margins and 20.69% net income margins, though Q1 2026 earnings missed expectations. Recent news highlights acquisition interest from Steel Partners at $16.75 per share and ongoing shareholder activism, creating both opportunity and uncertainty around corporate governance and valuation.

The stock presents a value opportunity with low P/E (12.52) and EV/EBITDA (5.37) multiples, but faces risks from earnings volatility, shareholder disputes, and potential undervaluation concerns. Analyst consensus leans neutral with 45% buy ratings, while technical indicators suggest range-bound trading near key support at $15. Investment appeal hinges on resolution of acquisition talks and sustained execution amid competitive pressures.

Mesoblast Limited

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.

Returns comparison

Trailing returns across standard periods

About InMode Ltd

InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.

Read more on INMD

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO